During breast cancer bone metastasis, because breast cancer cells secrete more MSP, the MSP-RON pathway is activated in the osteoclasts, resulting in bone destruction; however, treatment with the RON inhibitor BMS777607/ASLAN002 can reduce bone destruction and decrease the expression of osteolytic markers in patients with breast cancer (23). Here, MSMB is linked to breast carcinoma.